The Structural Sources of Adventurism: The Case of the California Gold Rush

1978 ◽  
Vol 83 (6) ◽  
pp. 1466-1490 ◽  
Author(s):  
Gary G. Hamilton
Keyword(s):  
Gold Rush

Art of the Gold Rush

1998 ◽  
Author(s):  
Janice T. Driesbach ◽  
Harvey L. Jones ◽  
Katherine Church Holland
Keyword(s):  
Gold Rush

From Hard Money to Branch Banking

2016 ◽  
Vol 93 (1) ◽  
pp. 26-44
Author(s):  
Larry Schweikart ◽  
Lynne Pierson Doti
Keyword(s):  
West Coast ◽  
Financial Sector ◽  
Gold Rush ◽  
Test Case ◽  
The West ◽  
Branch Banking

In Gold Rush–era California, banking and the financial sector evolved in often distinctive ways because of the Gold Rush economy. More importantly, the abundance of gold on the West Coast provided an interesting test case for some of the critical economic arguments of the day, especially for those deriving from the descending—but still powerful—positions of the “hard money” Jacksonians.

Black Gold and Paradise

2015 ◽  
Vol 97 (3) ◽  
pp. 240-243
Author(s):  
Steven A. Preston
Keyword(s):  
Los Angeles ◽  
Gold Rush ◽  
San Pedro

The presence and use of petroleum in the Los Angeles area date back to prehistoric times. The automobile-driven Black Gold Rush of the 1890s fueled the emergence of Los Angeles and its port at San Pedro. But oil also had its downsides. The following speakers will address oil-based growth, problems, remedies, and culture.

Targeted Protein Degradation: "The Gold Rush is On!"

2020 ◽  
Vol 7 (1) ◽  
pp. 4-16
Author(s):  
Daria Kotlarek ◽  
Agata Pawlik ◽  
Maria Sagan ◽  
Marta Sowała ◽  
Alina Zawiślak-Architek ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Protein Degradation ◽  
Small Molecule ◽  
Gold Rush ◽  
European Company ◽  
Drug Candidates ◽  
Protein Inhibition ◽  
Small Molecule Drug ◽  
Therapeutic Benefits ◽  
Talent Pool

Targeted Protein Degradation (TPD) is an emerging new modality of drug discovery that offers unprecedented therapeutic benefits over traditional protein inhibition. Most importantly, TPD unlocks the untapped pool of the proteome that to date has been considered undruggable. Captor Therapeutics (Captor) is the fourth global, and first European, company that develops small molecule drug candidates based on the principles of targeted protein degradation. Captor is located in Basel, Switzerland and Wroclaw, Poland and exploits the best opportunities of the two sites – experience and non-dilutive European grants, and talent pool, respectively. Through over $38 M of funding, Captor has been active in three areas of TPD: molecular glues, bi-specific degraders and direct degraders, ObteronsTM.

Sign in / Sign up

Export Citation Format

Share Document